This meta-analysis suggested that PCA3 is acceptable as a valuable diagnostic biomarker in the management of PCa, which is a non-invasive method with the acceptable sensitivity and specificity in the diagnosis of PCa to distinguish patients from healthy individuals. The gene discussed is PCA3; the disease is posterior cortical atrophy.